Clinical Trial

Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 31, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To explore the safety and efficacy of cryoablation combined with PD-1 antibody and bevacizumab for patients with hepatocellular carcinoma resistance to PD-1/L1 antibody.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06530784
Lead Sponsor Shanghai Zhongshan Hospital
Conditions Carcinoma, Hepatocellular
Enrollment 36 participants
Start Date 2024-07-31
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-05-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-31